AbbVie Inc.

153.80+0.6400+0.42%Vol 4.40M1Y Perf 34.05%
Jul 1st, 2022 16:04 DELAYED
BID151.00 ASK153.65
Open153.08 Previous Close153.80
Pre-Market- After-Market151.75
 - -  -2.05 -1.33%
Target Price
165.00 
Analyst Rating
Moderate Buy 1.97
Potential %
7.28 
Finscreener Ranking
+     38.37
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★+     42.98
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★+     48.54
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★★     37.63
Price Range Ratio 52W %
68.57 
Earnings Rating
Sell
Market Cap271.78B 
Earnings Date
29th Jul 2022
Alpha0.01 Standard Deviation0.08
Beta0.83 

Today's Price Range

151.46153.86

52W Range

105.56175.91

5 Year PE Ratio Range

11.9048.90

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
0.96%
1 Month
4.80%
3 Months
-5.46%
6 Months
13.59%
1 Year
34.05%
3 Years
107.19%
5 Years
112.11%
10 Years
-

TickerPriceChg.Chg.%
ABBV153.800.64000.42
AAPL138.932.21001.62
GOOG2 181.62-5.8300-0.27
MSFT259.582.75001.07
XOM87.551.91002.23
WFC39.920.75001.91
JNJ179.522.01001.13
FB196.640.99000.51
GE63.54-0.1300-0.20
JPM114.051.44001.28
Financial StrengthValueIndustryS&P 500US Markets
0.60
0.80
0.80
4.51
7.00
Leverage Ratio 10.10
ProfitabilityValueIndustryS&P 500US Markets
69.50
28.90
43.60
17.30
22.20
RevenueValueIndustryS&P 500US Markets
56.73B
32.10
20.25
16.25
DividendsValueIndustryS&P 500US Markets
3.68
5.64
8.98
17.50
Payout ratio134.00
Earnings HistoryEstimateReportedSurprise %
Q01 20223.153.160.32
Q04 20213.293.310.61
Q03 20213.233.333.10
Q02 20213.113.110.00
Q01 20212.772.956.50
Q04 20202.852.922.46
Q03 20202.752.832.91
Q02 20202.242.344.46
Earnings Per EndEstimateRevision %Trend
6/2022 QR3.43-1.72Negative
9/2022 QR3.67-1.08Negative
12/2022 FY14.02-0.78Negative
12/2023 FY11.86-4.12Negative
Next Report Date29th Jul 2022
Estimated EPS Next Report3.43
Estimates Count7
EPS Growth Next 5 Years %2.50
Volume Overview
Volume4.40M
Shares Outstanding1.77M
Shares Float1.77B
Trades Count57.41K
Dollar Volume673.28M
Avg. Volume6.53M
Avg. Weekly Volume6.26M
Avg. Monthly Volume6.23M
Avg. Quarterly Volume7.08M

AbbVie Inc. (NYSE: ABBV) stock closed at 153.8 per share at the end of the most recent trading day (a 0.42% change compared to the prior day closing price) with a volume of 4.40M shares and market capitalization of 271.78B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 50000 people. AbbVie Inc. CEO is Richard A. Gonzalez.

The one-year performance of AbbVie Inc. stock is 34.05%, while year-to-date (YTD) performance is 13.59%. ABBV stock has a five-year performance of 112.11%. Its 52-week range is between 105.56 and 175.91, which gives ABBV stock a 52-week price range ratio of 68.57%

AbbVie Inc. currently has a PE ratio of 21.90, a price-to-book (PB) ratio of 16.53, a price-to-sale (PS) ratio of 4.77, a price to cashflow ratio of 11.90, a PEG ratio of 2.32, a ROA of 8.70%, a ROC of 15.29% and a ROE of 84.89%. The company’s profit margin is 22.20%, its EBITDA margin is 43.60%, and its revenue ttm is $56.73 Billion , which makes it $32.10 revenue per share.

Of the last four earnings reports from AbbVie Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $3.43 for the next earnings report. AbbVie Inc.’s next earnings report date is 29th Jul 2022.

The consensus rating of Wall Street analysts for AbbVie Inc. is Moderate Buy (1.97), with a target price of $165, which is +7.28% compared to the current price. The earnings rating for AbbVie Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AbbVie Inc. has a dividend yield of 3.68% with a dividend per share of $5.64 and a payout ratio of 134.00%.

AbbVie Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 5.56, ATR14 : 3.68, CCI20 : 89.85, Chaikin Money Flow : 0.09, MACD : 1.10, Money Flow Index : 67.89, ROC : 11.76, RSI : 60.86, STOCH (14,3) : 86.48, STOCH RSI : 0.80, UO : 55.90, Williams %R : -13.52), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AbbVie Inc. in the last 12-months were: Brian L. Durkin (Option Excercise at a value of $1 363 676), Brian L. Durkin (Sold 30 418 shares of value $4 309 432 ), Carrie C. Strom (Sold 7 453 shares of value $945 083 ), Elaine K. Sorg (Option Excercise at a value of $809 669), Elaine K. Sorg (Sold 22 793 shares of value $2 937 436 ), Henry O. Gosebruch (Option Excercise at a value of $4 606 045), Henry O. Gosebruch (Sold 123 960 shares of value $18 919 823 ), Jeffrey Ryan Stewart (Option Excercise at a value of $1 630 387), Jeffrey Ryan Stewart (Sold 51 330 shares of value $7 869 429 ), Laura J. Schumacher (Option Excercise at a value of $10 381 360), Laura J. Schumacher (Sold 181 670 shares of value $23 660 677 ), Michael Severino (Option Excercise at a value of $41 222 566), Michael Severino (Sold 579 801 shares of value $88 227 551 ), Richard A. Gonzalez (Option Excercise at a value of $10 682 776), Richard A. Gonzalez (Sold 174 100 shares of value $21 453 641 ), Robert A. Michael (Sold 43 105 shares of value $6 390 245 ), Roxanne S. Austin (Sold 71 844 shares of value $8 377 984 ), Timothy J. Richmond (Option Excercise at a value of $2 964 608), Timothy J. Richmond (Sold 76 782 shares of value $9 960 768 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (53.33 %)
8 (53.33 %)
9 (64.29 %)
Moderate Buy
1 (6.67 %)
1 (6.67 %)
1 (7.14 %)
Hold
5 (33.33 %)
5 (33.33 %)
4 (28.57 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (6.67 %)
1 (6.67 %)
0 (0.00 %)
Summary RatingModerate Buy
1.97
Moderate Buy
1.97
Moderate Buy
1.64

AbbVie Inc.

AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

CEO: Richard A. Gonzalez

Telephone: +1 847 932-7900

Address: 1 North Waukegan Road, North Chicago 60064-6400, IL, US

Number of employees: 50 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

59%41%

Bearish Bullish

58%42%

TipRanks News for ABBV

Tue, 24 May 2022 02:06 GMT AbbVie (ABBV) Receives a New Rating from SVB Securities

- TipRanks. All rights reserved.

Thu, 12 May 2022 12:49 GMT AbbVie (ABBV) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Sat, 23 Apr 2022 03:28 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: AbbVie (ABBV) and Quest Diagnostics (DGX)

- TipRanks. All rights reserved.

Tue, 19 Apr 2022 16:08 GMT AbbVie: Why Its an Excellent Recession-Resistant Stock

- TipRanks. All rights reserved.

Fri, 15 Apr 2022 03:26 GMT AbbVie (ABBV) Gets a Buy Rating from Wells Fargo

- TipRanks. All rights reserved.

Tue, 12 Apr 2022 13:23 GMT AbbVie: Great Company, Future Upside Likely Weakened

- TipRanks. All rights reserved.

Fri, 11 Mar 2022 15:16 GMT AbbVie Stock: Strong Partnerships Bode Well

- TipRanks. All rights reserved.

Fri, 11 Mar 2022 14:18 GMT BMO Capital Believes AbbVie (ABBV) Still Has Room to Grow

- TipRanks. All rights reserved.

Thu, 10 Mar 2022 17:35 GMT Mizuho Securities Believes AbbVie (ABBV) Wont Stop Here

- TipRanks. All rights reserved.

Wed, 02 Mar 2022 16:37 GMT Analysts Conflicted on These Healthcare Names: Horizon Therapeutics (HZNP), AbbVie (ABBV) and NanoString Tech (NSTG)

- TipRanks. All rights reserved.

Mon, 07 Feb 2022 14:17 GMT AbbVie Stock Has Further to Climb

- TipRanks. All rights reserved.

Thu, 27 Jan 2022 12:37 GMT AbbVie (ABBV) Gets a Buy Rating from Mizuho Securities

- TipRanks. All rights reserved.

Wed, 05 Jan 2022 08:11 GMT What Do Neurocrines Newly Added Risk Factors Tell Investors

- TipRanks. All rights reserved.

News

Stocktwits